People: Pluristem Therapeutics Inc (PSTI.PH)

PSTI.PH on Philadelphia Stock Exchange

2.86USD
23 Apr 2015
Change (% chg)

-- (--)
Prev Close
$2.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
148
52-wk High
$3.65
52-wk Low
$2.35

Search Stocks

Summary

Name Age Since Current Position

Zami Aberman

60 2014 Chairman of the Board, Chief Executive Officer

Yaky Yanay

43 2014 President, Chief Operating Officer

Boaz Gur-Lavie

41 2014 Chief Financial Officer, Secretary

Doron Shorrer

62 2006 Lead Independent Director

Moria Kwiat

35 2012 Director

Hava Meretzki

46 2005 Director

Israel Ben-Yoram

54 2005 Independent Director

Issac Braun

62 2014 Independent Director

Mark Germain

64 2014 Independent Director

Nachum Rosman

69 2007 Independent Director

Karine Kleinhaus

2013 Divisional Vice President, North-America

Biographies

Name Description

Zami Aberman

Mr. Zami Aberman is Chairman of the Board, Chief Executive Officer of Pluristem Therapeutics, Inc. He changed the Company’s strategy towards cellular therapeutics. Mr. Aberman’s vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy, combined with the Company’s 3D culturing technology, led to the development of our products. Since November 2005, Mr. Aberman has served as a director of the Company, and since April 2006, as Chairman of the Board. He has 25 years of experience in marketing and management in the high technology industry. Mr. Aberman has held positions of CEO and Chairman positions in companies in Israel, the United States, Europe, Japan and Korea. Mr. Aberman operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. He serves as the Chairman of Rose Hitech Ltd., a private investment company. He served in the past as the Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a director of Ori Software Ltd., a company involved in data management. Prior to that, Mr. Aberman served as the President and CEO of Elbit Vision System Ltd. (EVSNF.OB), a company engaged in automatic optical inspection. Prior to his service with the Company, Mr. Aberman served as President and CEO of Netect Ltd., specializing in the field of internet security software and was the Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing. He also served as Chairman of Display Inspection Systems Inc., specializing in laser based inspection machines and as President and CEO of Robomatix Technologies Ltd.

Yaky Yanay

Mr. Yaky Yanay, CPA, is President, Chief Operating Officer of Pluristem Therapeutics, Inc. Until February 2014, he served as Pluristem’s Chief Financial Officer and Secretary since November 2006, and Executive Vice President since March 2013. Prior to joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd., a public company. Prior to that Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Mr. Yanay founded and served as Chairman of the “The Life Science Forum” in Israel and he is a member of the board of directors of Israel Advanced Technologies Industries (IATI), the largest umbrella organization in Israel for companies, organizations, and individuals in the high tech and life science sectors. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel.

Boaz Gur-Lavie

Mr. Boaz Gur-Lavie is Chief Financial Officer, Secretary of the Company. Prior to joining Pluristem, Mr. Gur-Lavie was CFO of Abbott Informatics Division, responsible for different Abbott Informatics brands and STARLIMS, a global software organization which helps laboratories optimize data accessibility, integrity, defensibility and long-term value. Before that, he served as VP Finance of STARLIMS, a software company that had been traded on the NASDAQ and Tel-Aviv Stock Exchange prior to being acquired by Abbott. Mr. Gur-Lavie previously served as assistant controller at ECI Telecom. Prior to that he served as a senior manager on the ERS team of Deloitte Israel. He also served as a lecturer at Ben Gurion University. Mr. Gur-Lavie holds a Master’s Degree in finance and a Bachelor’s Degree in economy and accounting from the University of Ben-Gurion. He is a Certified Public Accountant in Israel.

Doron Shorrer

Mr. Doron Shorrer, CPA, is Lead Independent Director of Pluristem Therapeutics, Inc. Mr. Shorrer was one of the Company’s founders and served as its first Chairman until 2006. Mr. Shorrer also serves as a director of other companies: Provident Fund for employees of the Israel Electric Company Ltd. and for Hebrew University employees, and Massad Bank from the International Bank group. Between 1999 and 2004 he was Chairman of the Boards of Phoenix Insurance Company, one of the largest insurance companies in Israel, and of Mivtachim Pension Funds Group, the largest pension fund in Israel. Prior to serving in these positions, Mr. Shorrer held senior positions that included Arbitrator at the Claims Resolution Tribunal for Dormant Accounts in Switzerland; Economic and Financial Advisor, Commissioner of Insurance and Capital Markets for the State of Israel; Member of the board of directors of “Nechasim” of the State of Israel; Member Committee for the Examination of Structural Changes in the Capital Market (The Brodet Committee); General Director of the Ministry of Transport; Founder and managing partner of an accounting firm with offices in Jerusalem, Tel-Aviv and Haifa; Member of the Lecture Staff of the Hebrew University Business Administration School; Chairman of Amal School Chain; Chairman of a Public Committee for Telecommunications; and Economic Consultant to the Ministry of Energy. Among many areas of expertise, Mr. Shorrer formulates implements and administers business planning in the private and institutional sector in addition to consulting on economic, accounting and taxation issues to a large audience ranging from private concerns to government ministries.

Moria Kwiat

Ms. Moria Kwiat serves as Director of Pluristem Therapeutics, Inc. Dr. Kwiat holds a B.Sc and an M.Sc. in Biotechnology from Tel Aviv University, and a Ph.D. from the Tel Aviv University Center for Nanoscience and Nanotechnology. Dr. Kwiat served as a teaching assistant at Tel Aviv University from 2003 through 2012. Currently, Dr. Kwiat is a postdoc fellow at the Faculty of Chemistry of Tel Aviv University, working on the development of new generation of biosensors based on nano-materials.

Hava Meretzki

Ms. Hava Meretzki is Director of Pluristem Therapeutics, Inc. Ms. Meretzki is an attorney and is a partner in Meretzki law firm in Haifa, Israel. Ms. Meretzki specializes in civil, trade and labor law, and is presently the Chairman of the National Council of the Israel Bar Association. Ms. Meretzki received a Bachelors Degree in Law from the Hebrew University in 1991 and was admitted to the Israel Bar Association in 1993.

Israel Ben-Yoram

Mr. Israel Ben-Yoram is Independent Director of Pluristem Therapeutics, Inc. He has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel since 1985. In addition, since 1992, Mr. Ben-Yoram has been a shareholder and has served as the head director of Mor, Ben-Yoram Ltd., a private company in Israel in parallel to the operation of Mor, Ben-Yoram and Partners. This company provides management services, economic consulting services and other professional services to businesses. Furthermore, Mr. Ben-Yoram is the CEO of Eshed Dash Ltd. and Zonbit Ltd. During 2003-2004 Mr. Ben-Yoram served as a director of Brainstorm Cell Therapeutics Inc. (BCLI) and Smart Energy solutions, Inc. (SMGY), both of which were traded on the NASDAQ.

Issac Braun

Mr. Issac Braun is Independent Director of Pluristem Therapeutics, Inc. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He is a co-founder and has been a board member of several hi-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun is involved with advising private companies on raising capital and business development.

Mark Germain

Mr. Mark S. Germain is Independent Director of Pluristem Therapeutics, Inc. Between May 2007 and February 2009, Mr. Germain served as Co-Chairman of our Board. For more than five years, Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries. He has been involved as a founder, director, chairman of the board of, and/or investor in, over twenty companies in the biotech field, and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated from New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law before leaving in 1986. Since then, and until he entered the biotech field in 1991, he served in senior executive capacities, including as president of a public company, which was sold in 1991. In addition to being a Director of the Company, Mr. Germain is a director of ChromaDex, Inc. (CDXB.OB), a publicly traded company. Mr. Germain also serves as a director of the following companies that were reporting companies in the past: Stem Cell Innovations, Inc., Omnimmune Corp. and Collexis Holdings, Inc. He is also a co-founder and director of a number of private companies in and outside the biotechnology field.

Nachum Rosman

Mr. Nachum Rosman is Independent Director of Pluristem Therapeutics, Inc. He provides management and consulting services to startup companies in the financial, organizational and human resource aspects of their operations. Mr. Rosman also serves as a director at several privately held companies. Throughout his career, Mr. Rosman held CEO and CFO positions in Israel, the United States and England. In these positions he was responsible, among other things, for finance management, fund raising, acquisitions and technology sales.

Karine Kleinhaus

Basic Compensation

Name Fiscal Year Total

Zami Aberman

1,035,550

Yaky Yanay

789,663

Boaz Gur-Lavie

352,531

Doron Shorrer

--

Moria Kwiat

--

Hava Meretzki

--

Israel Ben-Yoram

--

Issac Braun

--

Mark Germain

--

Nachum Rosman

--

Karine Kleinhaus

--
As Of  29 Jun 2014

Options Compensation

Name Options Value

Zami Aberman

0 0

Yaky Yanay

0 0

Boaz Gur-Lavie

0 0

Doron Shorrer

12,851,170 0

Moria Kwiat

0 0

Hava Meretzki

0 0

Israel Ben-Yoram

8,355,089 0

Issac Braun

8,284,594 0

Mark Germain

50,000,001 0

Nachum Rosman

0 0

Karine Kleinhaus

0 0
Search Stocks